格隆汇9月11日丨德琪医药(06996.HK)公告，9月11日耗资19.95万港元回购2.7万股。 ...

智通财经APP讯，德琪医药-B(06996)发布公告，于2025年9月11日，该公司斥资19.95万港元回购2.7万 股。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 德琪醫藥有限公司 呈交日期： 2025年9月11日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06996 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Hang Seng Bank, conducted share buybacks on September 10, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent [1]. Company-Specific Summaries - **Tencent Holdings (00700)**: - Repurchased 866,000 shares for a total of 550 million [2]. - Year-to-date total repurchased shares reached 53.884 million, accounting for 0.586% of total shares [2]. - **Hang Seng Bank (00011)**: - Repurchased 210,000 shares for a total of 24.8171 million [2]. - Year-to-date total repurchased shares reached 5.91 million, accounting for 0.314% of total shares [2]. - **China Hongqiao (01378)**: - Repurchased 980,000 shares for a total of 23.7363 million [2]. - Year-to-date total repurchased shares reached 149 million, accounting for 1.590% of total shares [2]. - **MGM China (02282)**: - Repurchased 1 million shares for a total of 16.0869 million [2]. - Year-to-date total repurchased shares reached 17.6274 million, accounting for 0.464% of total shares [2]. - **COSCO Shipping (02039)**: - Repurchased 742,900 shares for a total of 5.9284 million [2]. - Year-to-date total repurchased shares reached 11.2407 million, accounting for 0.360% of total shares [2]. - **Coolpad Group (02369)**: - Repurchased 1,036,000 shares for a total of 1.3156 million [2]. - Year-to-date total repurchased shares reached 11.595 million, accounting for 2.831% of total shares [2]. - **Other Notable Companies**: - Various companies such as Weigao Group, Mengniu Dairy, and others also participated in share buybacks, with amounts and shares varying significantly [2].

Summary of Key Points - The company, 德琪医药 (Dechra Pharmaceuticals), announced a share buyback on September 10, 2023, spending HKD 1.121 million to repurchase 146,000 shares [1]

格隆汇9月10日丨德琪医药(06996.HK)公告，9月10日耗资112.12万元回购A股股份14.6万股，每股回购 价7.61-7.69元。 ...

Group 1 - The company, 德琪医药-B (06996), announced a share buyback plan on September 10, 2025, with an expenditure of HKD 1.1213 million [1] - A total of 146,000 shares will be repurchased at a price range of HKD 7.61 to HKD 7.69 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 德琪醫藥有限公司 呈交日期： 2025年9月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06996 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德琪醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06996 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | 0.0001 | USD | | 200,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.0001 USD | | 200,000 | 本月底法定/ ...

Core Viewpoint - Dechra Pharmaceuticals-B (06996) has seen a significant increase in stock price, rising over 10% in the afternoon trading session, reflecting positive market sentiment following recent corporate announcements [1] Group 1: Share Buyback Announcement - The board of Dechra Pharmaceuticals has approved a share buyback plan, allowing the company to repurchase shares in the open market for a total price of up to 40 million HKD [1] - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] Group 2: Drug Development Update - Dechra Pharmaceuticals' ATG-022 has received breakthrough therapy designation from the National Medical Products Administration for treating CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma [1] - CMB International has raised its long-term and peak sales forecast for ATG-022 by nearly 30% and increased the company's DCF target price to 8.8 HKD, corresponding to a target market value of approximately 6 billion HKD and a peak sales revenue multiple of 2.1 times [1]